Gemini Therapeutics Inc
Change company Symbol lookup
Select an option...
GMTX Gemini Therapeutics Inc
F Ford Motor Co
CPB Campbell Soup Co
T AT&T Inc
GSS Golden Star Resources Ltd
TBNK Territorial Bancorp Inc
YUM Yum! Brands Inc
RTX Raytheon Technologies Corp
NAKD Naked Brand Group Ltd
FAMI Farmmi Inc

Health Care : Biotechnology |
Company profile

Gemini Therapeutics, Inc., formerly FS Development Corp., is a clinical-stage precision medicine company. The Company is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The Company's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH is a construct that express GEM103 continuously at a therapeutic level. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.

Closing Price
Day's Change
-0.22 (-8.43%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:



4 providers
November 01, 2021
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

Zoetis (ZTS) is set to report earnings and revenues, and provide updates on its diversified product portfolio when it releases third-quarter 2021 results.(Zacks)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.